Other Corporate Information – Page 7

2025-04-232025-05-28

Alligator Bioscience announces initiation of HLX22 Phase 2 trial in breast cancer by Shanghai Henlius Biotech, Inc.

Lund, Sweden – 23 April 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Shanghai Henlius Biotech, Inc. (“He ...

2025-04-012025-04-16

Regulatory

The board of directors of Alligator Bioscience AB (“Alligator Bioscience” or the “Company”) has resolved that the re ...

2025-03-21

Lund, Sweden – 21 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chi ...

2025-03-202025-05-28

Lund, Sweden – 20 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FD ...

2025-02-26

Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy alone Topline da ...

2025-02-25

Regulatory

The Board of Directors of Alligator Bioscience AB (“Alligator Bioscience” or the ”Company”) proposes that an Extraor ...

2025-02-24

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-02-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-02-14

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...